Home » Newsletters » BioWorld Science

BioWorld Science

June 24, 1998

View Archived Issues

Select Therapeutics signs agreement for cancer vaccine platform technology

Anseculin continues in phase II after successful testing in older volunteers

Abbott patents improved ketolide antibacterial agents

Substituted carbapenems for Gram-positive infections designed at Merck & Co.

Idun discloses new inhibitors of ICE and related proteases

Aspirin improves MS-related fatigue

S-16020-2: a topoisomerase II inhibitor selective for renal cancers heads for phase II testing

Progenics receives payment for cancer vaccine milestone

Miproxifene phosphate, a promising treatment for breast cancer

Management strategy including hydroxyurea successful in unresectable meningioma

Phase II evaluation of carzelesin in NHL

Sheffield and Zambon collaborate on MSI delivery system for respiratory drugs

Introgen Therapeutics acquires exclusive option to license PTEN gene

Duract withdrawn from the U.S. market due to reports of hepatotoxicity

Potent angiogenesis inhibitor AG-3340 profiled at NCI-EORTC symposium

Nabi licenses technology for development of antiviral drug

Canadian launch for improved antihypertensive medication

Draximage announces strategic alliance with Molecular Targeting Technology

Zeldox deemed nonapprovable by the FDA

Pharmacia & Upjohn licenses rights to novel JT diabetes drug

City of Hope identifies novel target for diabetes intervention as part of Cell City joint venture

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...